Search

Search Results

• 

  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

  M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

  278-285

  17-03-2014

  Published: 17 March 2014

  2468

  PDF: 1324
• 

  Are biological drugs safe in pregnancy?

  A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

  304-317

  31-03-2015

  Published: 31 March 2015

  3535

  PDF: 2326
• 

  On the history of biological drugs: the true discovery of the IL-1 receptor antagonist

  L. Punzi, P. Marson

  180

  19-07-2012

  Published: 19 July 2012

  695

  PDF (Italiano): 384
• 

  Possible relationship between certolizumab pegol and arrhythmias: report of two cases

  R. Talotta, F. Atzeni, A. Batticciotto, D. Ventura, P. Sarzi-Puttini

  104-108

  09-09-2016

  Published: 9 September 2016

  1453

  PDF: 920
• 

  The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study

  M. Manara, L. Arcarese, G. Bianchi, V. Corbelli, O. Epis, R. Laurenti, A. Migliore, M. Muratore, A. Roncaglione, M. Rossini, M. Savo, L. Sinigaglia

  188-194

  31-12-2016

  Published: 31 December 2016

  1622

  PDF: 891
• 

  IgA deficiency evidence after anti-TNF-α treatment in a psoriatic arthritis patient: case report

  S. Iervolino, M. Lofrano, M.N.D. Di Minno, F. Foglia, R. Scarpa, R. Peluso

  40-43

  19-03-2012

  Published: 19 March 2012

  853

  PDF: 1486
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  Published: 9 November 2011

  1295

  PDF: 1195

• Anti-TNFα agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients

  M. Filippini, C. Bazzani, S. Zingarelli, T. Ziglioli, M. Nuzzo, M. Vianelli, C. Biasini Rebaioli, R. Cattaneo, R. Gorla

  41-49

  Published:

  1129

  PDF: 757
• 

  Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients

  M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali

  17-07-2023

  Published: 17 July 2023

  799

  PDF: 471

• The bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects

  A. Corrado, F.P. Cantatore

  142-153

  11-04-2005

  Published: 11 April 2005

  852

  PDF: 1867

• Socio-demographic aspects and therapeutic pathways in patients with rheumatoid arthritis in Italy

  F. Salaffi, C.M. Vaccaro, T. Manacorda, L. Pardini, C.M. Montecucco

  197-211

  Published:

  1135

  PDF: 871

• Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

  P. Sarzi- Puttini, M. Antivalle, A. Marchesoni, E.G. Favalli, R. Gorla, M. Filippini, R. Caporali, F. Bobbio-Pallavicini, C. Montecucco, F. Atzeni

  290-295

  Published:

  1991

  PDF: 1037

• On the main stages of the history of intra-articular therapy

  P. Marson, G. Pasero, L. Punzi, G. Zanchin

  262-268

  Published:

  1293

  PDF: 1091

• Pregnancy in patients affected by axial-spondyloarthritis: a narrative review of disease activity and obstetric outcomes

  M. Filippini, G. Fontana, P. Bizioli, F. Crisafulli, R. Orabona, S. Zatti, F. Franceschini, A. Tincani

  11-09-2024

  Published: 11 September 2024

  545

  PDF: 264

• MonitorNet: studio italiano osservazionale multicentrico per la valutazione del profilo rischio-beneficio dei farmaci biologici nella pratica clinica reumatologica

  P. Sfriso, F. Salaffi, C.M. Montecucco, S. Bombardieri, S. Todesco

  132-139

  Published:

  1836

  PDF: 1104
• 

  The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis

  N. Ughi, R. Padoan, C. Crotti, S. Sciascia, G. Carrara, A. Zanetti, D. Rozza, S. Monti, D. Camellino, F. Muratore, G. Emmi, L. Quartuccio, S. Morbelli, K. El Aoufy, S. Tonolo, R. Caporali, S. De Vita, C. Salvarani, M.A. Cimmino

  07-02-2022

  Published: 7 February 2022

  8717

  PDF: 1896

• Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report

  M.G. Portuesi, P. Perosa

  61-63

  Published:

  1121

  PDF: 847
• 

  COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?

  Z. Ahmadinejad, R. Assari, N. Ayoobi Yazdi, S.-H. Mazloomi, P. Javanshayani, H. Khalili Afousi, V. Ziaee

  173-177

  19-11-2020

  Published: 19 November 2020

  1422

  PDF: 958
• 

  Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

  G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

  08-05-2023

  Published: 8 May 2023

  1262

  PDF: 727

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  Published:

  1093

  PDF: 1093
• 

  Severe Behçet’s disease equally affects both genders in Egyptian patients: A multicentre retrospective follow-up study

  D.H.S. Attia, R.A. Abdel Noor

  218-225

  28-01-2020

  Published: 28 January 2020

  1109

  PDF: 689

• Are there differences among anti-TNFa biological drugs?

  G. Valesini

  1-2

  Published:

  724

  PDF: 565

• Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

  S. Zingarelli, P. Airò, M. Frassi, C. Bazzani, M. Scarsi, M. Puoti

  22-27

  Published:

  1119

  PDF: 926